PASADENA, Calif., April 18, 2016 /PRNewswire/ -- Meditope Biosciences, Inc., a preclinical biotechnology company developing novel antibody-based products using its proprietary technology, today announced the presentation of data demonstrating the ability of its SnAP technology platform to facilitate cell surface receptor crosslinking and enhance antibody internalization. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16-20 in New Orleans.
"These data highlight additional commercial applications for our unique SnAP technology, showing that meditope-enabled antibodies using SnAP are a site selective way to attach molecules to antibodies, without interfering with normal antigen binding. Further, SnAP-induced crosslinking can promote enhanced internalization, facilitating antibody mediated cell death and cell signaling modulation," said Elisabeth Gardiner, Meditope Biosciences' Chief Scientific Officer and an author of the abstract. "We are highly encouraged by these results as we seek to advance our first antibody drug conjugate (ADC) product candidate into the clinic."
SnAP technology (Site-specific novel Antibody Platform) enables antibodies to bind to specific peptides called "meditopes," an ability that can be used to facilitate receptor crosslinking when meditope-enabled antibodies are bound to cell surface receptors. The poster presented at AACR, titled "Utilization of Meditope Biosciences SnAP Technology to Enhance Antibody Internalization" (Abstract #598) summarized an internalization experiment demonstrating how meditope-enabled antibody-to-antibody crosslinking leads to enhanced internalization.
Read more: http://www.prnewswire.com/news-releases/meditope-biosciences-announces-data-at-aacr-annual-meeting-demonstrating-further-capabilities-of-its-snap-technology-300252728.html